EUVIMEDEUVIMED entdecken
Open Access · CC BY-SA 4.0

Short-term CentriMag® Support in INTERMACS 1–2 Cardiogenic Shock: Lessons from A Single-Center Experience

Ekrem Yılmaz, Mehmet Balkanay, Murat Bülent Rabuş, Mehmet Erdem Toker, Mehmet Dedemoğlu, Fatih Yiğit, Taylan Adademir, Davit Saba

Koşuyolu Heart Journal · 01.07.2026 · 29 (2) · 107-113

DOI: 10.51645/khj.2026.565 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Koşuyolu Heart Journal, online erschienen am 12.06.2026. Verfasst von Ekrem Yılmaz und 7 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Acute cardiogenic shock (CS) developing in the setting of chronic heart failure is associated with high mortality and requires rapid hemodynamic intervention. This study aimed to evaluate the early outcomes of patients who received short-term mechanical circulatory support with the CentriMag® system for refractory CS and to assess the effectiveness of this strategy as a bridge therapy.

Methods

This retrospective, single-center study included 30 consecutive patients who had been listed for heart transplantation and underwent CentriMag® short-term ventricular assist device (VAD) implantation due to the development of CS between September 2010 and December 2013 in our hospital. CS was defined as persistent low cardiac output despite inotropic therapy and intra-aortic balloon pump support. The primary endpoints were survival to hospital discharge and successful bridging to recovery, durable support, or heart transplantation. Secondary endpoints included hemodynamic and laboratory improvement as well as device-related complications.

Results

The mean age of the patients was 32.7±15.2 years, and 70% were male. The mean left ventricular ejection fraction was 20.1%±4.0%. The most common etiologies of CS were idiopathic dilated cardiomyopathy (36.7%) and ischemic cardiomyopathy (26.7%). The most frequent post-operative complications were arrhythmia (36.6%), acute kidney injury (40%), and infection (33.3%). The mean duration of support was 33 days (range, 4–185). Eight patients (26.7%) were successfully bridged to heart transplantation and four (13.3%) to durable VAD support, while the 30-day survival rate was 60%.

Conclusion

The CentriMag® short-term VAD provided effective hemodynamic stabilization, improved end-organ function, and enabled bridging to durable support or heart transplantation in a substantial proportion of patients with refractory CS. Despite the high complication rates inherent in this critically ill population, the survival outcomes were more favorable compared with conventional therapy. The CentriMag® system appears to be a reliable bridge-to-decision or bridge-to-transplant option for patients with advanced heart failure presenting with acute CS.

Zitieren

APA

Yılmaz, E., Balkanay, M., Rabuş, M. B., Toker, M. E., Dedemoğlu, M., Yiğit, F., Adademir, T., & Saba, D. (2026). Short-term CentriMag® Support in INTERMACS 1–2 Cardiogenic Shock: Lessons from A Single-Center Experience. Koşuyolu Heart Journal, 29(2), 107-113. https://doi.org/10.51645/khj.2026.565

Vancouver

Yılmaz E, Balkanay M, Rabuş MB, Toker ME, Dedemoğlu M, Yiğit F, et al. Short-term CentriMag® Support in INTERMACS 1–2 Cardiogenic Shock: Lessons from A Single-Center Experience. Koşuyolu Heart Journal. 2026;29(2):107-113. doi:10.51645/khj.2026.565

BibTeX
@article{Ylmaz2026,
  author = {Yılmaz, Ekrem and Balkanay, Mehmet and Rabuş, Murat Bülent and Toker, Mehmet Erdem and Dedemoğlu, Mehmet and Yiğit, Fatih and Adademir, Taylan and Saba, Davit},
  title = {Short-term CentriMag® Support in INTERMACS 1–2 Cardiogenic Shock: Lessons from A Single-Center Experience},
  journal = {Koşuyolu Heart Journal},
  year = {2026},
  volume = {29},
  number = {2},
  pages = {107--113},
  doi = {10.51645/khj.2026.565}
}
Kostenlos starten →